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OBJECTIVE — Statins may exert pleiotropic effects on insulin action that are still controver-
sial. We assessed effects of high-dose simvastatin therapy on peripheral and hepatic insulin
sensitivity, as well as on ectopic lipid deposition in patients with hypercholesterolemia and type
2 diabetes.
RESEARCH DESIGN AND METHODS — We performed a randomized, double-blind,
placebo-controlled, single-center study. Twenty patients with type 2 diabetes received 80 mg
simvastatin (BMI 29  4 kg/m
2, age 55  6 years) or placebo (BMI 27  4 kg/m
2, age 58  8
years)dailyfor8weeksandwerecomparedwith10healthyhumans(controlsubjects;BMI27
4 kg/m
2, age 55  7 years). Euglycemic-hyperinsulinemic clamp tests combined with D-[6,6-
d2]glucose infusion were used to assess insulin sensitivity (M) and endogenous glucose produc-
tion (EGP).
1H magnetic resonance spectroscopy was used to quantify intramyocellular and
hepatocellular lipids.
RESULTS — High-dose simvastatin treatment lowered plasma total and LDL cholesterol lev-
els by 33 and 48% (P  0.005) but did not affect M, intracellular lipid deposition in soleus
and tibialis anterior muscles and liver, or basal and insulin-suppressed EGP. In simvastatin-
treatedpatients,changesinLDLcholesterolrelatednegativelytochangesinM(r0.796,P
0.01). Changes in fasting free fatty acids (FFAs) related negatively to changes in M (r  0.840,
P  0.01) and positively to plasma retinol-binding protein-4 (r  0.782, P  0.008).
CONCLUSIONS — High-dose simvastatin treatment has no direct effects on whole-body or
tissue-speciﬁc insulin action and ectopic lipid deposition. A reduction in plasma FFAs probably
mediates alterations in insulin sensitivity in vivo.
Diabetes Care 32:209–214, 2009
T
ype 2 diabetes is commonly associ-
ated with dyslipidemia, which rep-
resents a synergistic risk factor for
cardiovascular disease (1). High-
circulating lipids (free fatty acids [FFAs])
induce insulin resistance because of im-
paired muscle glucose transport/
phosphorylation, and intracellular lipids
in muscle (IMCLs) and liver (HCLs) pre-
dict insulin resistance (2).
Interventional studies emphasized
that statin treatment leads to a reduction
in cardiovascular events with beneﬁts for
patients with type 2 diabetes (3). Statins
could also contribute to diabetes preven-
tionowingtolipid-loweringandso-called
pleiotropic action. Statin therapy was
shown to improve endothelial function,
inhibit smooth muscle cell proliferation,
and reduce oxidative stress and inﬂam-
mation (4). Retrospective analysis of the
West of Scotland Coronary Prevention
Study (WOSCOPS) revealed that 5 years
of treatment with pravastatin reduced di-
abetes incidence by 30%. The authors
suggested that although lowering of tri-
glyceride levels could inﬂuence diabetes
incidence, other mechanisms such as
anti-inﬂammatory action may be in-
volved (5). However, pravastatin did not
decrease diabetes incidence in another
trial including glucose-intolerant hu-
mans, suggesting that early inception of
statin therapy may be required for effec-
tive diabetes prevention (6). Likewise,
simvastatin did not affect diabetes inci-
dence in patients with atherosclerosis in
the Heart Protection Study (7). In con-
trast, atorvastatin marginally increased
diabetes incidence in the Anglo-
Scandinavian Cardiac Outcomes Trial
(ASCOT-LLA), which could be explained
bystatisticalvariation(8).Thus,theeffect
of statins on diabetes incidence is still
uncertain.
The direct action of statins on insulin
sensitivity remains controversial because
beneﬁcial (9) and indifferent and unfa-
vorable(10)effectswerereported.Statins
not only decrease LDL cholesterol but
may also interfere with fasting and post-
prandial metabolism of triglyceride-rich
lipoproteins,resultinginalteredsubstrate
ﬂux and accumulation of HCLs (11,12),
which could subsequently affect muscle
glucose metabolism and deposition of
IMCLs.
Simvastatin is one of the most fre-
quently prescribed statins because of its
efﬁcacy in reducing LDL lipoprotein cho-
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duction of cardiovascular risk and
mortality (7). Its effects on insulin action
and metabolism at the maximal recom-
mended dose of 80 mg/day are unclear.
Thus, we examined the effects of 80 mg/
daysimvastatintherapyon1)insulinsen-
sitivity, 2) IMCLs and HCLs, 3) fasting
and insulin-mediated suppression of
plasmaFFAs,and4)-cellfunctionusing
euglycemic-hyperinsulinemic clamps
combined with stable isotope dilution
andnuclearmagneticresonancespectros-
copy in hypercholesterolemic, nor-
motriglyceridemic patients with type 2
diabetes.
RESEARCH DESIGN AND
METHODS— Twenty patients with
type 2 diabetes and hypercholesterolemia
were included. Eligibility criteria were
known duration of disease of 3–10 years,
age 35–75 years, BMI 32 kg/m
2, LDL
cholesterol 4.16 mmol/l, triglycerides
2.75 mmol/l, A1C 9%, serum creati-
nine 1.8 mg/dl, liver transaminases
20%overtheupperlimitwithnoactive
liver disease and creatine kinase 50%
above the upper limit, and no evidence of
metabolic diseases other than type 2 dia-
betes. Patients were taking neither lipid-
lowering drugs nor other drugs known to
interfere with metabolism of statins. The
only glucose-lowering drugs allowed
were metformin, sulfonylureas, and
-glucosidase inhibitors. Ten age-, sex-,
and BMI-matched healthy volunteers
(control subjects) were examined only at
baseline.
The study had a double-blind, ran-
domized, placebo-controlled and parallel
group design. The trial has been regis-
tered as a clinical trial. The sample size
was calculated using data from our previ-
ous studies in diabetic patients who com-
plied with the inclusion criteria of the
present study and were examined with
identical experimental methods. The
false-positive and false-negative error
rates tolerated were Z1.96 for a two-
tailed  of 0.05 and Z0.84 for a  of
0.2. An increase or decrease of 20% in
the mean values for the primary target
variables, insulin-stimulated whole-body
glucose disposal (M value) and insulin-
suppression of endogenous glucose pro-
duction (EGP), was considered to be
physiologically and clinically relevant.
The respective mean  SD values were
5  1m g  kg
1   min
1 for M values
(3  0.3 [ref. 13], 8  1 [ref. 14]), and
0.5  0.1 mg   kg
1   min
1 for EGP
suppression (13,14). These consider-
ations revealed a sample size of eight as
the minimal number of patients receiving
simvastatin. Expecting a dropout rate of
15%, we included 10 participants for
each study group.
After a run-in period of 3 weeks, the
patients were randomly assigned to treat-
ment with 80 mg daily simvastatin
(Merck Sharp & Dohme, Hoddesdon,
U.K.) or placebo for 2 months. Glucose
metabolism, IMCLs, and HCLs were de-
termined before and after treatment fol-
lowing overnight fasting for at least 12 h.
According to previous studies, sulfonyl-
ureas (three in the simvastatin group and
nine in the placebo group), metformin
(ﬁveinthesimvastatingroupandsevenin
theplacebogroup),and-glucosidasein-
hibitors(twointhesimvastatingroupand
one in the placebo group) were with-
drawn at 1 and 3 days before the clamps,
respectively (13,14). The study was ap-
provedbythelocalethicscommittee,and
patients consented to participate.
Glucose metabolism
At 7.00 A.M. patients were transferred to
the metabolic unit. A primed infusion of
D-[6,6-d2]glucose (3.6 mg/kg body
weight 	 [fasting plasma glucose/90])
followed by a continuous infusion (0.036
mg/min 	 kg body weight) was started to
determine EGP (15). At 9.00 A.M., a
primed continuous infusion of 40 mU/
min per m
2 body surface area was admin-
istered for 150 min to assess insulin sen-
sitivity (M) and the ratio of M to the
prevailing plasma insulin concentration
(M/I) by hyperinsulinemic-isoglycemic
(atbaselinefastingplasmaglucose[FPG])
clamps in control subjects and to stan-
dardize for increased FPG by a euglyce-
mic-hyperinsulinemic (100 mg/dl)
clamp in type 2 diabetic patients. In type
2 diabetic patients, euglycemia was
achieved by identical primed continuous
insulin infusions as in control subjects,
andnoadditionalinsulininfusionwasre-
quired. A 20% dextrose infusion, 2% en-
riched with D-[6,6-d2]glucose was
periodically adjusted to maintain eugly-
cemia (15).
Analytical procedures
Glucose was measured by the glucose ox-
idase method (Glucose Analyzer II; Beck-
man Instruments, Fullerton, CA). Atom
percent
2H enrichments in glucose were
determinedbygaschromatography–mass
spectrometry(15).FFAswereassayedmi-
croﬂuorimetrically (Wako Chemicals
USA, Richmond, VA) in blood samples
using orlistat to prevent in vitro lipolysis
(15). Triglyceride levels were measured
colorimetrically(Roche,Vienna,Austria).
Insulin, C-peptide, and glucagon were
determined by double-antibody radioim-
munoassay (15). Retinol-binding protein
(RBP)-4 was assayed nephelometrically
using an antiserum to human plasma RBP
(code OUVO; Dade Behring, Deerﬁeld,
IL) (16).
1H nuclear magnetic resonance
spectroscopy
Volunteers were lying supine inside a
1.5-Tspectrometer(Magnetom;Siemens,
Erlangen, Germany). HCLs were quanti-
ﬁed using a breath-hold–triggered single
voxel sequence without water suppres-
sion applied on the 27-cm
3 volume
within the right lateral liver (2). IMCLs
were determined in 1.73-cm
3 volumes
withinsoleusandtibialisanteriormuscles
using water-suppressed PRESS and the
AMARES algorithm as implemented in
the jMRUI software package. After T2 re-
laxation, IMCLs were quantiﬁed from the
intensity of the (CH2)n  1.25 ppm reso-
nance, which was compared with the wa-
ter resonance intensity obtained from
spectra without water suppression.
Calculations and statistics
The computer-solved homeostasis model
assessment (HOMA2) was used to derive
surrogate parameters of basal -cell func-
tion (HOMA-B) and insulin sensitivity
(HOMA-IR).EGPwascalculatedfromthe
difference between rates of glucose ap-
pearance (Ra) (15) and of mean glucose
infusion. Statistical analyses were per-
formed using SPSS software (version 6.0;
SPSS, Chicago, IL). Data are presented as
meansSD(SEMintheﬁgures).Com-
parisons between groups and drug-
induced effects were assessed by ANOVA
with or without repeated measurements
with Tukey post hoc testing. Within-
group differences were determined using
two-tailed Student’s t tests. Differences
were considered signiﬁcant at the 5%
level for M, FFAs, and EGP and at 1% for
other parameters to correct for interre-
lated comparison. Linear correlations are
Pearson product-moment correlations
and were considered to be signiﬁcant at
the 5% level for M, FFAs, and EGP and at
1% for all other relations.
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Baseline characteristics
Baseline characteristics of patients with
type 2 diabetes after allocation to either
placebo or simvastatin therapy and con-
trol subjects are shown in Table 1. A1C,
FPG, and triglycerides were increased in
both diabetic groups, and total choles-
terol and LDL cholesterol were slightly
higher in the simvastatin group than in
control subjects. In type 2 diabetic pa-
tients, HOMA-IR was 3.4-fold higher
than in control subjects, whereas
HOMA-B was comparable. 
-Glutamyl
transpeptidase (GGT) was 76 and
62% higher in type 2 diabetic patients
thanincontrolsubjects(P0.020versus
simvastatin; P  0.062 versus placebo).
Basal EGP was 21% higher in type 2
diabetic patients (simvastatin 1.7  0.3,
placebo 1.7  0.4, and control 1.4  0.4
mg kg
1 min
1;P0.05versustype2
diabetes). IMCLs in soleus and in tibialis
anterior muscles in type 2 diabetic pa-
tients were comparable to IMCLs in con-
trol subjects (simvastatin 1.4  0.5 and
0.2  0.2, placebo 1.3  0.6 and 0.3 
0.2, and control 1.5  0.9 and 0.4 
0.4%). In contrast, HCLs were 3.6-fold
higher in type 2 diabetic patients (simva-
statin 14.2  8.6, placebo 14.1  5.8,
and control 4  4%; P  0.001 versus
type 2 diabetes) (Fig. 1B). Across the
whole study population, HCLs tended to
relate positively to FPG (r  0.544, P 
0.005), A1C (r  0.409, P  0.05), and
GGT (r  0.442, P  0.05) without
reaching predeﬁned statistical signiﬁ-
cance (P  0.01) but related negatively
to M (r  0.386, P  0.05). IMCLs did
not correlate with any other metabolic
parameters.
Whole-body metabolism during the
clamps
Within 60 min of the clamps, plasma glu-
cose levels reached steady-state condi-
tions before and after treatment
(simvastatin 5.7  0.3 and 5.7  0.3,
placebo 5.9  0.6 and 5.7  0.2, and
control 4.9  0.4 mmol/l) and did not
differ within or among the intervention
groups. During the last 60 min of the
clamps, plasma glucose levels before and
after treatment were 5.4  0.3 and 5.4 
0.3 mmol/l in the simvastatin group,
5.5  0.3 and 5.4  0.3 mmol/l in the
placebo group, and 4.9  0.3 mmol/l in
control subjects and did not differ within
oramongtheinterventiongroupsbutwas
lower in control subjects than in type 2
diabetic patients (P  0.005). Plasma in-
sulinconcentrationswere580102and
609  109 pmol/l in the simvastatin
group, 537  80 and 551  94 pmol/l in
the placebo group, and 515  58 pmol/l
in control subjects and did not differ
within or among the intervention groups.
M values were 42% lower in type 2 di-
abetic patients and did not differ among
the intervention groups (control 7.4 
2.4, simvastatin 4.1  1.9, and placebo
4.5  2.7 mg   kg
1   min
1; P  0.005,
type 2 diabetic patients versus control
subjects) (Fig. 1A). Similarly, the M-to-I
ratio was lower in type 2 diabetic patients
[control subjects 0.01  0.005 mg   kg
1  
min
1   (pmol/l)
1; P  0.01] but not
different among intervention groups (Ta-
ble 2). Insulin-mediated suppression of
EGP (Table 2) and FFAs (control 94  5,
simvastatin 87  10, and placebo 92 
2%)wascomparableinallgroups.Plasma
triglycerides related positively to
HOMA-IR (r  0.683, P  0.00003) and
negativelytoM(r0.555,P0.001),
A1C (r  0.539, P  0.002), and FPG
(r  0.497, P  0.005).
Effects of simvastatin on lipid and
glucose metabolism
Intervention-related changes of plasma
lipids and glucose metabolism are shown
in Table 2. At 2 months, plasma total and
LDL cholesterol decreased by 33 and
48% in the simvastatin group but re-
mained unchanged in the placebo group.
There were no signiﬁcant changes in tri-
glycerides, HDL cholesterol, and fasting
FFAs after simvastatin therapy compared
withbaseline.Nevertheless,thesimvasta-
tin group had 29 and 35% lower tri-
glycerides and FFAs than the placebo
group. In the simvastatin group, the de-
creases in LDL cholesterol and FFAs were
positively associated (r  0.774, P 
0.001) but did not relate to changes in
triglycerides. Despite no signiﬁcant
changes in M after simvastatin treatment,
changes in FFAs were negatively corre-
lated with the change in M in the simva-
statin group (r  0.840, P  0.002),
which was weakened by the exclusion of
one subject with excessive changes in M
and FFAs (r  0.641, P  0.063). The
relationship between changes in M and
LDLcholesterol(r0.796,P0.006)
was completely lost by omission of this
subject (r  0.242, P  0.531) (Fig. 2A).
Adjustment for FFAs disrupted the rela-
tionshipbetweenthechangesinLDLcho-
lesterol and M (r  0.424, P  0.256),
whereas the association between changes
Table 1—Baseline characteristics of type 2 diabetic patients and matched nondiabetic volun-
teers
Simvastatin
(80 mg/day) Placebo
Control
subjects
n (women/men) 10 (3/7) 10 (5/5) 10 (5/5)
BMI (kg/m
2) 28.9  3.5 27.3  3.7 27.4  4
Age (years) 55  65 8  85 5  7
A1C (%) 6.7  0.6 6.7  0.7 5.6  0.2‡
FPG (mmol/l) 8.7  1.3 8.5  1.3 4.9  0.4§
HOMA-B 64  23 69  27 81  17
HOMA-IR 2.7  0.9 2.7  0.8 0.8  0.2
Fasting EGP (mg   kg
1   min
1) 1.7  0.3 1.7  0.4 1.4  0.4**
TGs (mmol/l) 1.7  0.5 1.9  0.6 1.1  0.4*†
FFAs (mol/l) 503  229 618  206 613  206
TC (mmol/l) 7.6  2.5 6.6  0.8 5.6  0.9*
TG-to-HDL cholesterol ratio 2.9  1.0 3.3  1.2 1.8  0.8¶
HDL cholesterol (mmol/l) 1.4  0.3 1.4  0.2 1.5  0.2
LDL cholesterol (mmol/l) 5.4  2.3 4.3  0.6 3.6  0.8*
ALT (units/l) 37  13 34  11 26  9
AST (units/l) 25  72 1  42 6  7
GGT (units/l) 37  13 34  11 21  12*
DataaremeanSDanthropometricandlaboratorycharacteristicsoftype2diabeticpatientsafterallocation
to either placebo or simvastatin therapy and healthy control subjects. BMI, FPG, surrogate parameters of
basal -cell function (HOMA-B) and basal insulin sensitivity (HOMA-IR), total triglycerides (TGs), FFAs,
total cholesterol levels (TC), HDL cholesterol and calculated LDL cholesterol, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and GGT were determined. *P  0.05, control versus simvastatin;
**P  0.05, control versus simvastatin and placebo; †P  0.005, control versus placebo; ‡P  0.0005,
simvastatin and placebo versus control; §P  0.00001, simvastatin and placebo versus control; P 
0.00005, simvastatin and placebo versus control; ¶P  0.01, placebo versus control.
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justment for LDL cholesterol (r  0.584,
P  0.099). Changes in the M-to-I ratio
after simvastatin treatment also related
positivelytochangesinplasmaFFAs(r
0.674, P  0.033). Plasma RBP-4 did not
differ between the groups (simvastatin
5.4  0.4 and placebo 5.0  0.5 mg/dl)
but tended to relate positively to
HOMA-IR (r  0.479, P  0.032). After
simvastatin treatment, plasma RBP-4 cor-
related with the change in FFAs (r 
0.782, P  0.008) (Fig. 2B). IMCLs and
HCLs remained unchanged (simvastatin
1.4  0.6, 0.3  0.3, and 11.0  6.5%
and placebo 1.7  1.0, 0.4  0.5, and
11.5  8.0%) (Fig. 1). Changes in insulin
sensitivity did not relate to muscle and
liverlipids.Also,basalEGPandEGPsup-
pression were not affected by treatment
(simvastatin 1.7  0.2 mg   kg
1   min
1
[72  14%] and placebo 1.5  0.4 mg  
kg
1   min
1 [74  12%]).
CONCLUSIONS
Effects on serum lipids
High-dose simvastatin treatment reduced
LDL cholesterol by 48% in agreement
with the maximum achievable LDL cho-
lesterol reduction. Increases in HDL cho-
lesterol and decreases in fasting
triglycerides and FFAs were not observed
in our patients with only slight hypertri-
Figure 1— Whole-body insulin sensitivity (M value) (A), ectopic lipid deposition in liver (B)
soleusmuscle(C),andanteriortibialismuscle(D)inpatientswithtype2diabetesbeforeandafter
treatment with 80 mg/day simvastatin (S, n  10, f) or placebo (P, n  10, o), and healthy
humans (CON, n  10,  , P  0.005 versus simvastatin and placebo groups).
Table 2—Effects of simvastatin on lipid proﬁles and glucose metabolism
Simvastatin (80 mg/day) Placebo
A1C (%) 6.7  0.6 (0.01  0.3) 6.7  0.6 (0.01  0.4)
HOMA-B 71  31 (6.8  16.6) 67  29 (1.3  1)
HOMA-IR 2.7  0.6 (0.03  0.6*) 3.3  1.2† (0.6  0.5)
M (mg   kg
1   min
1) 4.7  3.3 (0.6  2.1) 3.8  1.6 (0.3  2.0)
M-to-I ratio (mg   kg
1   min
1)   (pmol/l)
1 0.008  0.005 (0.002  0.01) 0.006  0.003 (0.001  0.008)
Rate of glucose disappearance (mg   kg
1   min
1) 5.3  3.1 (0.0  2.9) 4.0  1.3 (1.2  1.2)
EGP during clamp (mg   kg
1   min
1) 0.48  0.32 (0.29  0.95) 0.39  0.33 (0.01  0.60)
EGP suppression (%) 72  14 (3  13) 74  12 (4  16)
TGs (mmol/l) 1.5  0.4* (0.2  0.5*) 2.1  0.8 (0.3  0.4)
FFAs (mol/l) 392  130* (111  205) 600  234 (18  211)
TC (mmol/l) 5.1  1.0†‡ (2.5  1.8‡) 6.6  0.8 (0.0  0.6)
TG-to-HDL cholesterol ratio 2.7  1.2 (0.1  1.2) 3.7  1.7 (0.4  0.7)
HDL cholesterol (mmol/l) 1.4  0.3 (2.9  5.9) 1.4  0.3 (1.8  7.1)
LDL cholesterol (mmol/l) 2.8  0.9†‡ (2.6  1.6§) 4.2  0.5 (0.2  0.4)
ALT (units/l) 40  20 (6  16) 29  12 (2  5)
AST (units/l) 31  15 (6  14) 22  6( 1 5)
GGT (units/l) 39  23 (2  15) 36  8( 2 6)
RBP-4 (mg/dl) 5.0  1.1 (0.4  0.8) 5.8  1.7 (0.7  0.6)
Data are mean  SD laboratory characteristics of type 2 diabetic patients after treatment with 80 mg/day simvastatin for 8 weeks or application of placebo; changes
comparedwithbaselinearegiveninparentheses.Surrogateparametersofbasal-cellfunction(HOMA-B)andbasalinsulinsensitivity(HOMA-IR),totaltriglycerides
(TGs), whole-body glucose disposal (M), FFAs, total cholesterol levels (TC), HDL cholesterol and calculated LDL cholesterol, alanine aminotransferase (ALT),
aspartateaminotransferase(AST),GGT,andrateofglucosedisappearanceweredetermined.*P0.05simvastatinversusplacebo;†P0.005versusbaseline;‡P
0.005, simvastatin versus placebo; §P  0.0005, simvastatin versus placebo.
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fore, exert larger effects on HDL
cholesterol and triglycerides in more se-
vere hypertriglyceridemia.
Effects on insulin sensitivity
Simvastatin treatment slightly reduces in-
sulin sensitivity using the quantitative in-
sulin sensitivity check index (17) in line
withﬁndingsintype2diabetes(10).Oth-
ers reported that simvastatin does not
change (18) or increases insulin sensitiv-
ity(HOMA-IR)inseverelyhypertriglycer-
idemic, hypercholesterolemic patients
with type 2 diabetes (9). Only a few stud-
ies demonstrated changes in whole-body
insulin sensitivity by statin therapy with
the use of clamps (10,19). At a dose of 80
mg/day, we found no effect of simvastatin
on whole-body insulin sensitivity in
nonobese type 2 diabetes with good met-
abolic control. This ﬁnding does not ex-
clude a speciﬁc simvastatin effect on
hepatic insulin sensitivity. Our patients
withtype2diabetesexhibitedmarkedhe-
patic insulin resistance indicated by only
70% EGP suppression. However, sim-
vastatin did not ameliorate EGP suppres-
sioninourpatientswithtype2diabetes,a
resultthatisinlinewiththeonlyprevious
study on pravastatin treatment in familial
hypercholesterolemia (20). Statins not
only decrease LDL cholesterol but may
also interfere with fasting and postpran-
dial triglyceride-rich lipoprotein metabo-
lism, resulting in altered substrate ﬂux
and accumulation of HCLs (11,12,21).
Our patients exhibited a tight correlation
between excessive HCL storage and M
value similar to that in previous reports
(2).SimvastatindidnotaffecteitherHCLs
or IMCLs in two muscles with different
compositions. Also no relationship be-
tween changes in insulin sensitivity and
ectopic lipids was found.
Effects on parameters inﬂuencing
insulin sensitivity
According to current paradigms, mecha-
nisms determining insulin sensitivity
comprise 1) circulating FFAs arising from
adipocyte lipolysis, lipoprotein secretion,
or dietary fat intake, 2) cytokines from
adipose tissue or liver, and 3) low-grade
inﬂammation. Recently, simvastatin was
found to improve FFA composition, fast-
ing lipid fractions, and postprandial
plasma triglycerides even in normotri-
glyceridemic patients (21). In the present
study, a reduction in plasma FFAs during
the clamp, reﬂecting insulin-mediated
suppression of lipolysis, remained un-
changedaftertherapy.Statinscouldaffect
insulin resistance via declining plasma
triglycerides in type 2 diabetes. Triglycer-
ide levels were negatively related to M at
baselineandchangesinfastingFFAswere
found to induce considerable effects on
insulin sensitivity. Accordingly, evidence
is accumulating that intracellular long-
chain fatty acyl CoA and diacylglycerol
inhibit muscular insulin action by stimu-
lating serine phosphorylation of insulin
receptor substrate-1 rather than IMCLs
(22).
Statins may further affect inﬂamma-
tory markers (4), which could relate to
changed adipocytokines. Circulating
RBP-4,producedmainlybyadipocytes,is
related to whole-body insulin sensitivity
and is elevated in insulin-resistant states
(23), but its role remains controversial
(16). Here we show that serum RBP-4 re-
lates to a surrogate of fasting insulin sen-
sitivity and to changes in plasma FFAs
upon simvastatin therapy. Nevertheless,
serumRBP-4didnotrelatetowhole-body
insulinsensitivityasassessedfromtheeu-
glycemic clamp and simvastatin did not
affect RBP-4.
Effects on fasting -cell function
High-dose lipophilic statins may induce
unfavorable pleiotropic effects including
impairment of insulin secretion (24,25).
The proposed mechanism suggests that
these statins inhibit the glucose-induced
elevation of free [Ca
2] in cytoplasm,
thereby diminishing insulin secretion.
However, other studies reported in-
creased or unchanged fasting insulin
(9,10). We found no changes in either
fasting insulin or HOMA-B during simva-
statin therapy.
Somelimitationsofthisstudyneedto
be considered. First, the number of par-
ticipants per treatment group is low but
was based on a sample size calculation
considering that increases of whole-body
and hepatic insulin sensitivity by 20%
represent a clinically relevant treatment
effect. Second, only patients with un-
treated hypercholesterinemia in need of
cholesterol-lowering drug treatment ac-
cording to current guidelines were in-
cluded. Thus, this trial comprised a
typicalbutpreselectedpopulation,which
doesnotallowextrapolationoftheresults
tonormolipidemictype2diabeticornon-
diabeticpopulations.Third,theextensive
metabolic characterization revealed a
high number of parameters assessed so
that the level of signiﬁcance was adjusted
to correct for interrelated comparison.
Nevertheless, despite the extensive meta-
bolic characterization by gold-standard
Figure 2— Correlation of changes in fasting FFAs with the changes in whole-body insulin sensitivity (M value) (A) and RBP-4 (B) in patients with
type 2 diabetes before and after treatment with 80 mg/day simvastatin (S, n  10).
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toryandantioxidantmechanismsthatpo-
tentially affect insulin action were not
explored in the present study. As a result,
the issue of whether a possible dissocia-
tion exists among different pleiotropic ef-
fects of statins cannot be completely
resolved. Finally, different glucose-
lowering drugs were used in both groups
and withdrawn before the clamp. How-
ever,antidiabeticmedicationdidnothave
any impact on whole-body and hepatic
insulin sensitivity and patients taking
thiazolidinediones or insulin were not in-
cluded in this study.
Thus, this study shows that even
high-dose simvastatin treatment that ef-
fectively reduces LDL cholesterol does
not directly improve either whole-body
orhepaticinsulinsensitivityorintracellu-
lar lipid deposition in near normotriglyc-
eridemic patients with type 2 diabetes.
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